Actinium Pharmaceuticals, Inc . , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Joseph Jurcic, Chairman of Actinium's Clinical Advisory Board, will participate in the "Combination Therapy: Proposals for Success " panel discussion at the Cancer Advance Boston conference at Harvard Medical School.
http://ift.tt/1mIC0jP
http://ift.tt/1mIC0jP
No comments:
Post a Comment